A Phase 2 interventional study of Upadacitinib and Placebo in Atopic Dermatitis, sponsored by AbbVie. Completed at 34 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-07-16.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.
Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 11th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 2, and was the 1st registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
RenJi Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 167 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 272 across the 17 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
34 studies in Dermatitis, Atopic by AbbVie: 3 open now, 12 under way, 4 of them phase 3. Of 19 finished, 8 (42%) have results posted.
Among the 34 studies in Dermatitis, Atopic by AbbVie, this one is the 14th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2016, is one of 6 in phase 2, and was the 1st registered.
AbbVie’s Dermatitis, Atopic studies by the year they started, since 2016.
3 of the studies testing upadacitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT06701331Phase 3AbbVieSafety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis | 2027-01 |
| NCT07678645RenJi HospitalThe Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing upadacitinib in Dermatitis, Atopic, from their registry updates:
Among AbbVie’s 34 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The objective of this study was to evaluate the safety and efficacy of multiple doses of upadacitinib monotherapy versus placebo in the treatment of adults with moderate to severe atopic dermatitis (AD).
The study was to include a 16-week double-blind treatment period (Period 1) and a 72-week double-blind treatment period (Period 2) for a total of 88 weeks of treatment. Participants who met eligibility criteria were to be randomized in a 1:1:1:1 ratio to one of the four treatment groups. Participants who completed Period 1 were re-randomized at Week 16 into a 72-week double-blind, placebo-controlled treatment period (Period 2) in a 1:1 ratio:
In Period 1, discontinuation from study drug was mandatory for any participant with an Eczema Area and Severity Index (EASI) score worsening of 25% or more compared with their Baseline EASI score at any 2 consecutive scheduled study visits from Week 4 to Week 12.
In Period 2, blinded rescue therapy with upadacitinib 30 mg QD was provided after the first instance of a \< EASI 50 response starting at the Week 20 visit (4 weeks after re-randomization into Period 2) for the remainder of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive placebo once daily (QD) for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo once a day for 72 weeks in Period 2.
Drug: Upadacitinib · Drug: Placebo
Participants randomized to receive upadacitinib 7.5 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 7.5 mg upadacitinib or placebo QD for 72 weeks in Period 2.
Drug: Upadacitinib · Drug: Placebo
Participants randomized to receive upadacitinib 15 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 15 mg upadacitinib or placebo QD for 72 weeks in Period 2.
Drug: Upadacitinib · Drug: Placebo
Participants randomized to receive upadacitinib 30 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo QD for 72 weeks in Period 2.
Drug: Upadacitinib · Drug: Placebo
Tablet for oral use
Also known as: RINVOQ™, ABT-494
Tablet
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from baseline indicates improvement.
Time frame: Baseline and Week 16
Percentage of Participants Who Achieved a 75% Reduction in EASI Score (EASI 75) at Week 16
EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 75 response is defined as participants with at least a 75% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at Week 16 were counted as non-responders in this analysis (non-responder imputation).
Time frame: Baseline and Week 16
Percentage of Participants Achieving an Investigator Global Assessment (IGA) of "0" or "1" at Week 16
The Investigator's Global Assessment for Atopic Dermatitis (IGA) was scored on the following scale: * 0: Clear (No inflammatory signs of atopic dermatitis) * 1: Almost Clear (Just perceptible erythema and just perceptible papulation/infiltration) * 2: Mild (Mild erythema and mild papulation/infiltration) * 3: Moderate (Moderate erythema and moderate papulation/infiltration) * 4: Severe (Severe erythema and severe papulation/infiltration with or without oozing/crusting) The percentage of participants with a score of 0 or 1 at Week 16 is reported.
Time frame: Week 16
Percent Change From Baseline to Weeks 2, 8, and 16 in Pruritus Numerical Rating Scale (NRS)
Participants were asked to rate pruritus (itch) in the past 24 hours on a daily basis using a scale from 0 to 10, with 0 being no itch and 10 being the worst imaginable itch. The percent change from Baseline at each week was calculated from a rolling weekly average.
Time frame: Baseline and Weeks 2, 8, and 16
Percent Change From Baseline in EASI Score at Week 8
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
Time frame: Baseline and Week 8
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Weeks 8 and 16
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.
Time frame: Baseline and Weeks 8 and 16
Percentage of Participants Who Achieved an EASI 75 Response at Week 8
EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 75 response is defined as participants with at least a 75% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at Week 8 were counted as non-responders in this analysis (non-responder imputation).
Time frame: Baseline and Week 8
Percentage of Participants Who Achieved an EASI 50 Response at Weeks 8 and 16
EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 50 response is defined as participants with at least a 50% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at each time point were counted as non-responders in this analysis (non-responder imputation).
Time frame: Baseline and Weeks 8 and 16
Percentage of Participants Who Achieved an EASI 90 Response at Weeks 8 and 16
EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 90 response is defined as participants with at least a 90% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at each time point were counted as non-responders in this analysis (non-responder imputation).
Time frame: Baseline and Weeks 8 and 16
Percentage of Participants Who Achieved a SCORAD 50 Response at Weeks 8 and 16
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 50 response is defined as participants with at least a 50% reduction (improvement) in SCORAD score relative to the Baseline value. Participants with missing values were counted as non-responders in this analysis (non-responder imputation).
Time frame: Baseline and Weeks 8 and 16
Percentage of Participants Who Achieved a SCORAD 75 Response at Weeks 8 and 16
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 75 response is defined as participants with at least a 75% reduction (improvement) in SCORAD score relative to the Baseline value. Participants with missing values were counted as non-responders in this analysis (non-responder imputation).
Time frame: Baseline and Weeks 8 and 16
Percentage of Participants Who Achieved a SCORAD 90 Response at Weeks 8 and 16
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 90 response is defined as participants with at least a 90% reduction (improvement) in SCORAD score relative to the Baseline value. Participants with missing values were counted as non-responders in this analysis (non-responder imputation).
Time frame: Baseline and Weeks 8 and 16
Percent Change From Re-randomization (Week 16) in EASI Score in Period 2
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
Time frame: Re-randomization (Week 16) and Weeks 20, 24, 32, 40, 52, 64, 76, and 88
Time to Loss of EASI 50 Response Relative to Baseline Among Participants Re-randomized as EASI 75 Responders at Week 16
Time to loss of EASI 50 response in Period 2 relative to Baseline among those who were re-randomized as EASI 75 responders at Week 16. Time to loss of EASI 50 response was measured from Week 16 to the date of the first assessment in Period 2 where a participant's EASI score was higher than 50% of their Baseline score. Participants with no loss of response were censored at their last treatment visit or the start of rescue treatment, whichever occurred first.
Time frame: From re-randomization at Week 16 until Week 88
Percentage of Participants With an EASI 75 Response in Period 2 in Participants Who Were Re-randomized as EASI 75 Non-responders at Week 16
EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) in EASI score relative to the Baseline value, and was analyzed in participants who were re-randomized at Week 16 and were EASI 75 non-responders at Week 16.
Time frame: Weeks 20, 24, 32, 40, 52, 64, 76, and 88
Percentage of Participants Who Achieved a Dermatology Life Quality Index (DLQI) of "0" or "1" at Weeks 8 and 16
The DLQI is a 10-item questionnaire that asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week in the following 6 aspects: symptoms and feelings, daily activities, leisure, work or school activities, personal relationships and treatment related feelings. Participants answer the 10 questions on a scale from 0 (not at all) to 3 (very much). The DLQI is calculated by summing the scores of the 10 questions, resulting in a maximum of 30 and a minimum of 0 with higher scores indicating more impaired quality of life. A score of 0 or 1 means that the disease has no effect at all. Dermatology Life Quality Index outcomes were defined but are not reported because of an error in the programming of the electronic device used to administer the questionnaire that precluded determination of these outcomes.
Time frame: Weeks 8 and 16
Change From Baseline in DLQI at Weeks 8 and 16
The DLQI is a 10-item questionnaire that asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week in the following 6 aspects: symptoms and feelings, daily activities, leisure, work or school activities, personal relationships and treatment related feelings. Participants answer the 10 questions on a scale from 0 (not at all) to 3 (very much). The DLQI is calculated by summing the scores of the 10 questions, resulting in a maximum of 30 and a minimum of 0 with higher scores indicating more impaired quality of life. A negative change from Baseline indicates improvement. Dermatology Life Quality Index outcomes were defined but are not reported because of an error in the programming of the electronic device used to administer the questionnaire that precluded determination of these outcomes.
Time frame: Baseline and Weeks 8 and 16
Change From Baseline in Percentage of Body Surface Area (BSA) Affected by Atopic Dermatitis at Week 16
Body surface area (BSA) affected by atopic dermatitis was assessed by the physician and is expressed as a percentage of the total BSA. For purposes of the estimation, the total surface of the participant's palm plus five digits was assumed to be approximately equivalent to 1% BSA. Last observation carried forward imputation was used.
Time frame: Baseline and Week 16
Percentage of Participants With Reduction of ≥ 4 Points From Baseline in Pruritus NRS at Week 16
Participants were asked to rate pruritus (itch) in the past 24 hours on a daily basis using a scale from 0 to 10, with 0 being no itch and 10 being the worst imaginable itch. The percentage of participants with reduction of ≥ 4 points from Baseline in pruritus NRS was assessed in participants with a baseline pruritus NRS of ≥ 4. Participants with missing values at Week 16 were counted as non-responders in this analysis (non-responder imputation).
Time frame: Baseline and Week 16
Participants were enrolled at 36 sites in 8 countries (Australia, Canada, Finland, Germany, Japan, Netherlands, Spain, and the United States \[US\]). The study included a 16-week double-blind treatment period (Period 1) followed by a a 72-week double-blind treatment period (Period 2) for a total of 88 weeks of treatment.
| Milestone | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Placebo / Placebo | Placebo / Upadacitinib 30 mg | Upadacitinib 7.5 mg / Placebo | Upadacitinib 7.5 mg / Upadacitinib 7.5 mg | Upadacitinib 15 mg / Placebo | Upadacitinib 15 mg / Upadacitinib 15 mg | Upadacitinib 30 mg / Placebo | Upadacitinib 30 mg / Upadacitinib 30 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 41 | 42 | 42 | 42 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received treatment | 40 | 42 | 42 | 42 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 23 | 31 | 37 | 39 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 18 | 11 | 5 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 3 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 10 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 5 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Placebo / Placebo | Placebo / Upadacitinib 30 mg | Upadacitinib 7.5 mg / Placebo | Upadacitinib 7.5 mg / Upadacitinib 7.5 mg | Upadacitinib 15 mg / Placebo | Upadacitinib 15 mg / Upadacitinib 15 mg | Upadacitinib 30 mg / Placebo | Upadacitinib 30 mg / Upadacitinib 30 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 10 | 10 | 15 | 16 | 19 | 18 | 19 | 19 |
| Rescued to upadacitinib 30 mg | 0 | 0 | 0 | 0 | 8 | 1 | 13 | 12 | 17 | 12 | 14 | 4 |
| Completed | 0 | 0 | 0 | 0 | 8 | 5 | 9 | 11 | 13 | 12 | 11 | 14 |
| Not completed | 0 | 0 | 0 | 0 | 2 | 5 | 6 | 5 | 6 | 6 | 8 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 3 | 2 | 2 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 4 | 3 | 0 |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from baseline indicates improvement.
| percent change | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16 | -23.0 ± 6.42 | -39.4 ± 6.24 | -61.7 ± 6.12 | -74.4 ± 6.13 |
EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 75 response is defined as participants with at least a 75% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at Week 16 were counted as non-responders in this analysis (non-responder imputation).
| percentage of participants | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants Who Achieved a 75% Reduction in EASI Score (EASI 75) at Week 16 | 9.8 | 28.6 | 52.4 | 69.0 |
The Investigator's Global Assessment for Atopic Dermatitis (IGA) was scored on the following scale: * 0: Clear (No inflammatory signs of atopic dermatitis) * 1: Almost Clear (Just perceptible erythema and just perceptible papulation/infiltration) * 2: Mild (Mild erythema and mild papulation/infiltration) * 3: Moderate (Moderate erythema and moderate papulation/infiltration) * 4: Severe (Severe erythema and severe papulation/infiltration with or without oozing/crusting) The percentage of participants with a score of 0 or 1 at Week 16 is reported.
| percentage of participants | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving an Investigator Global Assessment (IGA) of "0" or "1" at Week 16 | 2.4 | 14.3 | 31.0 | 50.0 |
Participants were asked to rate pruritus (itch) in the past 24 hours on a daily basis using a scale from 0 to 10, with 0 being no itch and 10 being the worst imaginable itch. The percent change from Baseline at each week was calculated from a rolling weekly average.
| percent change | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Week 2 | 1.7 ± 5.59 | -29.3 ± 5.45 | -46.0 ± 5.44 | -57.6 ± 5.24 |
| Week 8 | -6.7 ± 7.51 | -35.5 ± 7.28 | -45.1 ± 7.32 | -73.1 ± 7.05 |
| Week 16 | -9.7 ± 8.30 | -39.6 ± 8.04 | -48.0 ± 8.08 | -68.9 ± 7.79 |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
| percent change | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percent Change From Baseline in EASI Score at Week 8 | -17.5 ± 6.27 | -43.7 ± 6.09 | -65.4 ± 5.97 | -82.8 ± 5.98 |
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.
| percent change | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Week 8 | -7.0 ± 5.84 | -35.4 ± 5.53 | -44.1 ± 5.69 | -65.3 ± 5.52 |
| Week 16 | -12.4 ± 5.97 | -32.5 ± 5.66 | -46.9 ± 5.82 | -60.4 ± 5.65 |
EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 75 response is defined as participants with at least a 75% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at Week 8 were counted as non-responders in this analysis (non-responder imputation).
| percentage of participants | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants Who Achieved an EASI 75 Response at Week 8 | 7.3 | 31.0 | 52.4 | 81.0 |
EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 50 response is defined as participants with at least a 50% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at each time point were counted as non-responders in this analysis (non-responder imputation).
| percentage of participants | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Week 8 | 22.0 | 54.8 | 71.4 | 92.9 |
| Week 16 | 22.0 | 50.0 | 71.4 | 83.3 |
EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 90 response is defined as participants with at least a 90% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at each time point were counted as non-responders in this analysis (non-responder imputation).
| percentage of participants | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Week 8 | 0.0 | 9.5 | 26.2 | 45.2 |
| Week 16 | 2.4 | 14.3 | 26.2 | 50.0 |
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 50 response is defined as participants with at least a 50% reduction (improvement) in SCORAD score relative to the Baseline value. Participants with missing values were counted as non-responders in this analysis (non-responder imputation).
| percentage of participants | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Week 8 | 7.3 | 33.3 | 42.9 | 76.2 |
| Week 16 | 7.3 | 28.6 | 42.9 | 61.9 |
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 75 response is defined as participants with at least a 75% reduction (improvement) in SCORAD score relative to the Baseline value. Participants with missing values were counted as non-responders in this analysis (non-responder imputation).
| percentage of participants | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Week 8 | 0.0 | 9.5 | 9.5 | 31.0 |
| Week 16 | 2.4 | 4.8 | 21.4 | 40.5 |
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 90 response is defined as participants with at least a 90% reduction (improvement) in SCORAD score relative to the Baseline value. Participants with missing values were counted as non-responders in this analysis (non-responder imputation).
| percentage of participants | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Week 8 | 0.0 | 4.8 | 2.4 | 14.3 |
| Week 16 | 0.0 | 2.4 | 9.5 | 23.8 |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
| percent change | Placebo / Placebo | Placebo / Upadacitinib 30 mg | Upadacitinib 7.5 mg / Placebo | Upadacitinib 7.5 mg / Upadacitinib 7.5 mg | Upadacitinib 15 mg / Placebo | Upadacitinib 15 mg / Upadacitinib 15 mg | Upadacitinib 30 mg / Placebo | Upadacitinib 30 mg / Upadacitinib 30 mg |
|---|---|---|---|---|---|---|---|---|
| Week 20 | 50.7 ± 33.50 | 11.8 ± 30.59 | 186.0 ± 46.53 | 79.1 ± 48.42 | 582.3 ± 172.19 | 65.7 ± 178.24 | 791.5 ± 262.34 | -73.8 ± 215.54 |
| Week 24 | 13.5 ± 17.13 | -67.5 ± 15.64 | 189.6 ± 44.17 | 59.0 ± 45.97 | 607.3 ± 169.49 | 72.6 ± 175.44 | 898.5 ± 248.78 | -69.6 ± 200.01 |
| Week 32 | -2.3 ± 15.15 | -83.1 ± 13.83 | 181.5 ± 44.74 | 63.5 ± 46.56 | 613.3 ± 169.63 | 151.7 ± 175.59 | 771.5 ± 252.90 | -28.8 ± 210.78 |
| Week 40 | -31.2 ± 18.16 | -92.0 ± 16.58 | 200.9 ± 41.58 | 77.6 ± 43.27 | 608.8 ± 169.95 | 154.1 ± 175.92 | 778.9 ± 344.45 | 140.6 ± 293.17 |
| Week 52 | -29.8 ± 17.74 | -90.1 ± 16.20 | 189.1 ± 43.65 | 74.4 ± 45.42 | 613.8 ± 166.85 | 104.1 ± 164.05 | 799.5 ± 254.30 | -13.3 ± 216.44 |
| Week 64 | -35.8 ± 17.34 | -91.4 ± 15.83 | 179.9 ± 44.91 | 71.8 ± 46.74 | 614.6 ± 166.57 | 104.1 ± 163.78 | 802.1 ± 278.76 | 63.6 ± 237.26 |
| Week 76 | -37.3 ± 19.09 | -90.3 ± 17.43 | 201.4 ± 41.89 | 77.7 ± 43.60 | 614.0 ± 168.03 | 130.2 ± 169.29 | 787.8 ± 262.89 | 24.4 ± 219.11 |
| Week 88 | -37.7 ± 19.18 | -84.6 ± 17.51 | 170.7 ± 46.87 | 69.1 ± 48.78 | 617.5 ± 165.84 | 99.3 ± 163.06 | 769.7 ± 265.64 | 39.0 ± 226.10 |
Time to loss of EASI 50 response in Period 2 relative to Baseline among those who were re-randomized as EASI 75 responders at Week 16. Time to loss of EASI 50 response was measured from Week 16 to the date of the first assessment in Period 2 where a participant's EASI score was higher than 50% of their Baseline score. Participants with no loss of response were censored at their last treatment visit or the start of rescue treatment, whichever occurred first.
| days | Placebo / Placebo | Placebo / Upadacitinib 30 mg | Upadacitinib 7.5 mg / Placebo | Upadacitinib 7.5 mg / Upadacitinib 7.5 mg | Upadacitinib 15 mg / Placebo | Upadacitinib 15 mg / Upadacitinib 15 mg | Upadacitinib 30 mg / Placebo | Upadacitinib 30 mg / Upadacitinib 30 mg |
|---|---|---|---|---|---|---|---|---|
| Time to Loss of EASI 50 Response Relative to Baseline Among Participants Re-randomized as EASI 75 Responders at Week 16 | NA (NA to NA) | NA (NA to NA) | 29 (27 to NA) | NA (29 to NA) | 30 (17 to 55) | 114 (29 to NA) | 28 (25 to 36) | NA (NA to NA) |
EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) in EASI score relative to the Baseline value, and was analyzed in participants who were re-randomized at Week 16 and were EASI 75 non-responders at Week 16.
| percentage of participants | Placebo / Placebo | Placebo / Upadacitinib 30 mg | Upadacitinib 7.5 mg / Placebo | Upadacitinib 7.5 mg / Upadacitinib 7.5 mg | Upadacitinib 15 mg / Placebo | Upadacitinib 15 mg / Upadacitinib 15 mg | Upadacitinib 30 mg / Placebo | Upadacitinib 30 mg / Upadacitinib 30 mg |
|---|---|---|---|---|---|---|---|---|
| Week 20 | 11.1 | 12.5 | 0 | 9.1 | 0 | 12.5 | 20.0 | 25.0 |
| Week 24 | 100 | 85.7 | — | 33.3 | 0 | 0 | 33.3 | 33.3 |
| Week 32 | 100 | 100 | — | 0 | 0 | 50.0 | 50.0 | 50.0 |
| Week 40 | 100 | 66.7 | — | — | 0 | 100 | 0 | 50.0 |
| Week 52 | 100 | 66.7 | — | — | 0 | 100 | — | 50.0 |
| Week 64 | 100 | 80.0 | — | — | 0 | 100 | — | 100 |
| Week 76 | 100 | 100 | — | — | 0 | 100 | — | 100 |
| Week 88 | 100 | 100 | — | — | 0 | 100 | — | 100 |
The DLQI is a 10-item questionnaire that asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week in the following 6 aspects: symptoms and feelings, daily activities, leisure, work or school activities, personal relationships and treatment related feelings. Participants answer the 10 questions on a scale from 0 (not at all) to 3 (very much). The DLQI is calculated by summing the scores of the 10 questions, resulting in a maximum of 30 and a minimum of 0 with higher scores indicating more impaired quality of life. A score of 0 or 1 means that the disease has no effect at all. Dermatology Life Quality Index outcomes were defined but are not reported because of an error in the programming of the electronic device used to administer the questionnaire that precluded determination of these outcomes.
No measurements were reported for this outcome.
The DLQI is a 10-item questionnaire that asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week in the following 6 aspects: symptoms and feelings, daily activities, leisure, work or school activities, personal relationships and treatment related feelings. Participants answer the 10 questions on a scale from 0 (not at all) to 3 (very much). The DLQI is calculated by summing the scores of the 10 questions, resulting in a maximum of 30 and a minimum of 0 with higher scores indicating more impaired quality of life. A negative change from Baseline indicates improvement. Dermatology Life Quality Index outcomes were defined but are not reported because of an error in the programming of the electronic device used to administer the questionnaire that precluded determination of these outcomes.
No measurements were reported for this outcome.
Body surface area (BSA) affected by atopic dermatitis was assessed by the physician and is expressed as a percentage of the total BSA. For purposes of the estimation, the total surface of the participant's palm plus five digits was assumed to be approximately equivalent to 1% BSA. Last observation carried forward imputation was used.
| percentage of body surface area | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Change From Baseline in Percentage of Body Surface Area (BSA) Affected by Atopic Dermatitis at Week 16 | -4.1 ± 3.58 | -11.7 ± 3.48 | -27.1 ± 3.43 | -30.7 ± 3.43 |
Participants were asked to rate pruritus (itch) in the past 24 hours on a daily basis using a scale from 0 to 10, with 0 being no itch and 10 being the worst imaginable itch. The percentage of participants with reduction of ≥ 4 points from Baseline in pruritus NRS was assessed in participants with a baseline pruritus NRS of ≥ 4. Participants with missing values at Week 16 were counted as non-responders in this analysis (non-responder imputation).
| percentage of participants | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants With Reduction of ≥ 4 Points From Baseline in Pruritus NRS at Week 16 | 5.7 | 24.3 | 59.4 | 52.8 |
Collected over From the first dose of study drug up to 30 days after last dose. Period 1: 16 weeks, Period 2: 72 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Placebo | 0/40 (0%) | 1/40 (2.5%) | 15/40 (37.5%) |
| Period 1: Upadacitinib 7.5 mg | 0/42 (0%) | 2/42 (4.8%) | 21/42 (50%) |
| Period 1: Upadacitinib 15 mg | 0/42 (0%) | 1/42 (2.4%) | 17/42 (40.5%) |
| Period 1: Upadacitinib 30 mg | 0/42 (0%) | 0/42 (0%) | 21/42 (50%) |
| Period 1+2: Upadacitinib 7.5 mg | 0/42 (0%) | 2/42 (4.8%) | 23/42 (54.8%) |
| Period 1+2: Upadacitinib 15 mg | 0/42 (0%) | 1/42 (2.4%) | 22/42 (52.4%) |
| Period 1+2: Upadacitinib 30 mg | 2/114 (1.8%) | 7/114 (6.1%) | 68/114 (59.6%) |
| Period 1+2: Placebo | 0/93 (0%) | 1/93 (1.1%) | 19/93 (20.4%) |
| Event | Period 1: Placebo | Period 1: Upadacitinib 7.5 mg | Period 1: Upadacitinib 15 mg | Period 1: Upadacitinib 30 mg | Period 1+2: Upadacitinib 7.5 mg | Period 1+2: Upadacitinib 15 mg | Period 1+2: Upadacitinib 30 mg | Period 1+2: Placebo |
|---|---|---|---|---|---|---|---|---|
| ATRIAL FIBRILLATIONCardiac disorders | 1/40 | 0/42 | 0/42 | 0/42 | 0/42 | 0/42 | 0/114 | 1/93 |
| APPENDICITISInfections and infestations | 0/40 | 0/42 | 1/42 | 0/42 | 0/42 | 1/42 | 0/114 | 0/93 |
| PERICORONITISInfections and infestations | 0/40 | 1/42 | 0/42 | 0/42 | 1/42 | 0/42 | 0/114 | 0/93 |
| SKIN INFECTIONInfections and infestations | 0/40 | 1/42 | 0/42 | 0/42 | 1/42 | 0/42 | 0/114 | 0/93 |
| DERMATITIS ATOPICSkin and subcutaneous tissue disorders | 0/40 | 1/42 | 0/42 | 0/42 | 1/42 | 0/42 | 0/114 | 0/93 |
| CARDIO-RESPIRATORY ARRESTCardiac disorders | 0/40 | 0/42 | 0/42 | 0/42 | 0/42 | 0/42 | 1/114 | 0/93 |
| PERICARDITISCardiac disorders | 0/40 | 0/42 | 0/42 | 0/42 | 0/42 | 0/42 | 1/114 | 0/93 |
| OESOPHAGEAL FISTULAGastrointestinal disorders | 0/40 | 0/42 | 0/42 | 0/42 | 0/42 | 0/42 | 1/114 | 0/93 |
| SEPSISInfections and infestations | 0/40 | 0/42 | 0/42 | 0/42 | 0/42 | 0/42 | 1/114 | 0/93 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/40 | 0/42 | 0/42 | 0/42 | 0/42 | 0/42 | 1/114 | 0/93 |
| Event | Period 1: Placebo | Period 1: Upadacitinib 7.5 mg | Period 1: Upadacitinib 15 mg | Period 1: Upadacitinib 30 mg | Period 1+2: Upadacitinib 7.5 mg | Period 1+2: Upadacitinib 15 mg | Period 1+2: Upadacitinib 30 mg | Period 1+2: Placebo |
|---|---|---|---|---|---|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 4/40 | 7/42 | 5/42 | 5/42 | 7/42 | 7/42 | 26/114 | 5/93 |
| DERMATITIS ATOPICSkin and subcutaneous tissue disorders | 2/40 | 5/42 | 2/42 | 4/42 | 6/42 | 5/42 | 22/114 | 2/93 |
| ACNESkin and subcutaneous tissue disorders | 1/40 | 4/42 | 2/42 | 6/42 | 4/42 | 2/42 | 13/114 | 1/93 |
| NASOPHARYNGITISInfections and infestations | 1/40 | 2/42 | 4/42 | 3/42 | 3/42 | 5/42 | 11/114 | 1/93 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 2/40 | 0/42 | 3/42 | 4/42 | 0/42 | 3/42 | 7/114 | 3/93 |
| HEADACHENervous system disorders | 1/40 | 3/42 | 3/42 | 4/42 | 3/42 | 3/42 | 7/114 | 2/93 |
| HERPES ZOSTERInfections and infestations | 0/40 | 0/42 | 0/42 | 0/42 | 0/42 | 0/42 | 10/114 | 0/93 |
| NAUSEAGastrointestinal disorders | 1/40 | 3/42 | 1/42 | 3/42 | 3/42 | 1/42 | 6/114 | 2/93 |
| INFLUENZAInfections and infestations | 0/40 | 3/42 | 0/42 | 0/42 | 3/42 | 0/42 | 3/114 | 0/93 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 0/40 | 3/42 | 0/42 | 0/42 | 3/42 | 0/42 | 0/114 | 0/93 |
All randomized participants (intent-to-treat population)
| Age, Continuous(years) | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|
| Mean | 39.9 ± 17.52 | 41.5 ± 15.36 | 38.5 ± 15.24 | 39.9 ± 15.30 | 39.9 ± 15.77 |
| Age, Customized(Participants) | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|
| < 40 years | 25 | 22 | 25 | 22 | 94 |
| 40 - 64 years | 11 | 16 | 14 | 17 | 58 |
| ≥ 65 years | 5 | 4 | 3 | 3 | 15 |
| Sex: Female, Male(Participants) | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|
| Female | 17 | 14 | 12 | 20 | 63 |
| Male | 24 | 28 | 30 | 22 | 104 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 | 1 | 5 |
| Not Hispanic or Latino | 41 | 40 | 40 | 41 | 162 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|
| White | 28 | 24 | 21 | 23 | 96 |
| Black or African American | 6 | 7 | 10 | 6 | 29 |
| Asian | 7 | 9 | 9 | 13 | 38 |
| American Indian/Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 1 | 0 | 3 |
| Geographic Region(Participants) | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|
| US/Canada | 29 | 29 | 29 | 29 | 116 |
| EU/Australia | 10 | 11 | 10 | 10 | 41 |
| Japan | 2 | 2 | 3 | 3 | 10 |
| Duration of Atopic Dermatitis Diagnosis(years) | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|
| Mean | 26.84 ± 18.76 | 30.44 ± 18.07 | 22.59 ± 15.78 | 24.24 ± 13.58 | 26.02 ± 16.76 |
| Eczema Area and Severity Index (EASI)(units on a scale) | Placebo | Upadacitinib 7.5 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|
| Mean | 32.62 ± 14.49 | 31.42 ± 15.76 | 31.40 ± 12.26 | 28.15 ± 11.62 | 30.89 ± 13.61 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Oct 2016 to primary completion in Aug 2017, 9 months.
Results were first posted in Jul 2020, 2 years 11 months after primary completion. A results delay was requested in Aug 2018.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 9 months is below that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib